HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p.

AbstractBACKGROUND:
Irisin is a newly discovered myokine that has been considered a promising candidate for the treatment of cardiovascular disease through improving endothelial function. However, little is known about the role of irisin in the progression of atherosclerosis.
METHODS AND RESULTS:
We used a carotid partial ligation model of apolipoprotein E-deficient mice fed on a high-cholesterol diet to test the anti-atherosclerosis effect of irisin. Irisin treatment significantly suppressed carotid neointima formation. It was associated with increased endothelial cell proliferation. In addition, irisin promoted human umbilical vein endothelial cell survival via upregulating microRNA126-5p expression through the ERK signaling pathway. Inhibition of microRNA126-5p using the microRNA126-5p inhibitor abolished the prosurvival effect. The same results were demonstrated in vivo as the expression of microRNA126-5p noticeably increased in ligated carotid artery after irisin treatment. Furthermore, in vivo blockade of microRNA126-5p expression using the antagomir abolished the inhibitory effects of irisin on neointima formation, lesional lipid deposition, macrophage area, and the pro-proliferation effects on endothelial cells.
CONCLUSIONS:
Taken together, our study demonstrates that irisin significantly reduces atherosclerosis in apolipoprotein E-deficient mice via promoting endothelial cell proliferation through microRNA126-5p, which may have a direct therapeutic effect on atherosclerotic diseases.
AuthorsYuzhu Zhang, Haibo Song, Yuan Zhang, Fei Wu, Qian Mu, Miao Jiang, Fang Wang, Wen Zhang, Liang Li, Lei Shao, Shiwu Li, Lijun Yang, Mingxiang Zhang, Qi Wu, Dongqi Tang
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 5 Issue 9 (Sep 26 2016) ISSN: 2047-9980 [Electronic] England
PMID27671318 (Publication Type: Journal Article)
Copyright© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: